TGTX
Tg Therapeutics, Inc.
A biopharmaceutical company focused on B-cell-driven diseases, most notably multiple sclerosis. Its main product, BRIUMVI (ublituximab), is an infusion approved by the US FDA in 2022 to treat relapsing forms of MS. The firm traces roots to 1993 but took the TG Therapeutics name around 2012 under biotech veteran Michael Weiss, and the "TG" initials are commonly tied to its founders.
CUSIP: 88322Q108HealthcareUS1 holder
Total Value
$23.62M
Total Shares
429.9K
Net Share Change
+118.5K
Activity
1 buying
Investor
Value
Shares
Weight
Change
